Table 1. Demographics and clinical outcome according to the susceptibility of the index UTI to TMP-SMX.
| Variables | Total patients | Susceptible group | Resistant group | P value | ||
|---|---|---|---|---|---|---|
| Demographics | ||||||
| No. | 81 (100) | 42 (51.9) | 39 (48.1) | |||
| Age, mon | ||||||
| Median | 5.3 | 6.6 | 4.8 | |||
| Group | 0.258 | |||||
| 2–6 | 64 (79.0) | 30 (71.4) | 34 (87.2) | |||
| 7–11 | 11 (13.6) | 8 (19.0) | 3 (7.7) | |||
| > 12 | 6 (7.4) | 4 (9.5) | 2 (5.1) | |||
| Sex | 0.184 | |||||
| Male | 67 (82.7) | 37 (88.1) | 30 (76.9) | |||
| Female | 14 (17.3) | 5 (11.9) | 9 (23.1) | |||
| Highest grade of VUR | 0.044 | |||||
| Grade I | 1 (1.2) | 0 (0) | 1 (2.6) | |||
| Grade II | 6 (7.4) | 6 (14.3) | 0 (0) | |||
| Grade III | 25 (30.9) | 15 (35.7) | 10 (25.6) | |||
| Grade IV | 23 (28.4) | 10 (23.8) | 13 (33.3) | |||
| Grade V | 26 (32.1) | 11 (26.2) | 15 (38.5) | |||
| Bilateral VUR | 42 (51.9) | 21 (50.0) | 21 (53.8) | 0.729 | ||
| Initial renal scarring | 54 (66.7) | 29 (69.0) | 25 (64.1) | 0.637 | ||
| Index UTI pathogen | < 0.001 | |||||
| Escherichia coli | 47 (58.0) | 34 (81.0) | 13 (33.3) | |||
| Enterococcus | 15 (18.5) | 1 (2.4) | 14 (35.9) | |||
| Klebsiella | 7 (8.6) | 1 (2.4) | 6 (15.4) | |||
| Enterobacter | 6 (7.4) | 3 (7.1) | 3 (7.7) | |||
| Proteus | 4 (5.0) | 3 (7.1) | 1 (2.6) | |||
| Pseudomonas | 2 (2.5) | 0 (0) | 2 (5.1) | |||
| Clinical outcome | ||||||
| Breakthrough UTI | 34 (42.0) | 13 (31.0) | 21 (53.8) | 0.037 | ||
| Renal scarring f/u DMSA scan | 58 (71.6) | 29 (69.0) | 29 (74.4) | 0.596 | ||
| New or worsening renal scarring | 6 (7.4) | 0 (0) | 6 (15.4) | 0.053 | ||
| Spontaneous resolution | 26 (32.1) | 18 (42.9) | 8 (20.5) | 0.031 | ||
Data are presented as median or number (%).
UTI = urinary tract infection, TMP-SMX = trimethoprim-sulfamethoxazole, VUR = vesicoureteral reflux, DMSA = dimercaptosuccinic acid scan, f/u = follow up.